Interestingly, crossing SmoA1+/+ mice with Tet1 knockout mice led to a dramatic delay in age-of-onset of medulloblastoma-associated symptoms in SmoA1+/+;Tet1+/− (median survival 18.86 weeks versus undetermined) and a decrease in incidence of MB (42.7% versus 82.2% at 20 weeks; p < 0.0001; log-rank test) (Fig. 4a, Additional file 1: Fig. S4a), while no significant effects were observed upon crossing with Tet2 knockout mice (p = 0.8435; log-rank test, Fig. 4b, Additional file 1: Fig. S4a). Here, TET2 is linked to medulloblastoma.